Φορτώνει......
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
The management of advanced renal cell carcinoma (RCC) has dramatically changed over the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have considerably expanded treatment options; however, most patients with advance...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Nat Rev Urol |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5532875/ https://ncbi.nlm.nih.gov/pubmed/27324121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrurol.2016.103 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|